MyAverix Finance MyAverix Finance

V · Financial Services

NeuroThera Labs Inc. (NTLX)

Drug Manufacturers - General

NeuroThera Labs Inc. (NTLX) is listed on V in the Financial Services sector. Industry: Drug Manufacturers - General. As of 2026-03-23, reported P/E ratio is 18.00. Use this page for a quick overview, then open the MyAverix Finance app for income statements, balance sheet, cash flow, and news.

Data as of 2026-03-23

Download on the App Store Get it on Google Play

Download free on iPhone and Android

Key metrics for NTLX

P/E ratio
18.00

NeuroThera Labs Inc. (NTLX) — FAQ

What is NTLX's P/E ratio?

The price-to-earnings (P/E) ratio for NeuroThera Labs Inc. (NTLX) is 18.00 (data as of 2026-03-23).

Does NeuroThera Labs Inc. pay a dividend?

Dividend yield is not available in the current snapshot for NeuroThera Labs Inc. (NTLX). Check the MyAverix Finance app for the latest dividend data.

What sector is NeuroThera Labs Inc. in?

NeuroThera Labs Inc. (NTLX) is classified in the Financial Services sector (Drug Manufacturers - General industry).

What exchange is NTLX listed on?

NTLX is listed on V.

Full report in the app

Get the full report in the MyAverix Finance app — income, balance sheet, cash flow, ratios, and multi-year trends in one place.

Related Financial Services companies

Administradora Americana de Inversiones S.A. (AAISA) Aflac Incorporated (A1FL34) Agricultural Bank Of China (1288) AIA Group Ltd (1299) American International Group, Inc. (AIGB34) Ameriprise Financial Inc. (A1MP34) Arthur J. Gallagher & Co. (A1JG34) Banco Santander S.A. (BSD2)

← All stocks

MyAverix Finance provides company information and financial data for educational and research purposes only. We are not a broker, advisor, or investment service. Data may be delayed or incomplete. Past performance does not guarantee future results. Always do your own research before making financial decisions.

Terms of Use

App Store Google Play